Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer

Fatigue Clinical Trial

Official title:

A Pilot Study of Modafinil for Treatment of Fatigue and Neurobehavioral Dysfunction in Adult Brain Tumor Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00052286
• Other study ID #: CDR0000258139
• Secondary ID: UCLA-0206017CEPH
• Status: Completed
• Phase: N/A
• Start date: September 2002
• Est. completion date: August 2010

Study information

• Verified date: February 2016
• Source: Jonsson Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Modafinil may be effective in relieving fatigue and improving behavioral changes such as memory loss in patients who have undergone treatment for primary brain cancer. The effectiveness of modafinil in relieving fatigue and improving behavioral change is not yet known.

PURPOSE: This randomized clinical trial is comparing how well two different doses of modafinil work in treating fatigue and behavioral changes in patients who have undergone treatment for primary brain cancer.

Description:

OBJECTIVES:

• Compare the effectiveness of low-dose vs high-dose modafinil for treatment of fatigue and neurobehavioral dysfunction in patients with primary brain tumors.

• Determine the safety of this drug in these patients.

• Compare quality of life of patients treated with 2 different doses of this drug.

OUTLINE: This is a randomized, double-blind, parallel-group study. Patients are randomized to 1 of 2 arms.

• Randomized phase:

• Arm I: Patients receive oral high-dose modafinil twice daily.

• Arm II: Patients receive oral low-dose modafinil twice daily. In both arms, treatment in this phase continues for 3 weeks followed by a 1-week washout period.

• Extended treatment phase:After the 1-week washout period, all patients receive oral low-dose modafinil once daily on days 1-3. The dose is then titrated to an optimal level and administered in divided doses.

Fatigue, neurobehavioral dysfunction, and quality of life are assessed during the randomized phase at baseline and on days 7 and 21 and then during the extended treatment phase at baseline and on days 28 and 56.

PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: August 2010
• Est. primary completion date: July 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosis of primary malignant brain tumor and receiving treatment in the UCLA Neuro-Oncology Program

• Nonmalignant cerebral tumors also allowed

• Received some combination of prior therapy for disease, including neurosurgical resection, radiotherapy, and cytotoxic or cytostatic chemotherapy

• Mild to severe fatigue and/or attention/memory impairment, as measured by the Clinical Global Impression of Severity Scale

• Age 21 to 65

• Able to speak English

• Capable of completing self-rating scales and one-on-one psychometric tests

• Negative pregnancy test

• Fertile patients must use effective contraception

• Concurrent conventional chemotherapy (e.g., carboplatin, lomustine, temozolomide) allowed

• Concurrent glucocorticoids (e.g., dexamethasone) allowed

• Concurrent tamoxifen allowed

• At least 30 days since prior stimulants (e.g., amphetamines or methylphenidate)

• Concurrent anticonvulsants allowed

• Concurrent isotretinoin allowed

Exclusion Criteria:

• Have significant hepatic disease, defined as SGOT greater than or equal to 2.5 times the upper limit of normal.

• Have significant renal disease, defined as creatinine greater than or equal to 1.5mg/dl.

• severe cognitive impairment

• other terminal illness

• emergency patient

• institutional resident

• prisoner or parolee

• UCLA students or staff

• pregnant or nursing

• concurrent irinotecan

• concurrent participation in UCLA experimental chemotherapy trials

• prior modafinil

• concurrent experimental anticancer medication

• concurrent tricyclic antidepressants and/or monoamine oxidase inhibitors

Related Conditions & MeSH terms

• Brain and Central Nervous System Tumors
• Central Nervous System Neoplasms
• Cognitive/Functional Effects
• Fatigue
• Nervous System Neoplasms

Intervention

Drug:
• modafinil

Locations

Country	Name	City	State
United States	Jonsson Comprehensive Cancer Center at UCLA	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
Jonsson Comprehensive Cancer Center	Cephalon

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neurocognitive functioning		at baseline and weeks 1, 3, 4, 8, and 10
Secondary	Global functioning as assessed by Clinical Global Impression of Severity and Clinical Global Impression of Change.		at baseline and weeks 1, 3, 4, 5, 7, 8, 9, and 10